KPV vs LL-37.
Quick Verdict
KPV is a anti-inflammatory primarily researched for gut/injury healing, inflammation reduction, while LL-37 is a antimicrobial peptide studied for broad-spectrum antimicrobial, anti-biofilm, wound healing, immune modulation, anti-inflammatory. A key distinction: LL-37 has FDA approval status.
Side-by-Side Analysis
| Dimension | KPV | LL-37 |
|---|---|---|
| Category | Anti-Inflammatory | Antimicrobial Peptide |
| Mechanism | Alpha-MSH fragment that potently suppresses NF-κB inflammatory signaling. | The only human cathelicidin antimicrobial peptide. |
| Half-Life | ~30 minutes | ~4 hours |
| Route | SubQ | SubQ |
| Typical Dose | 200–200 mcg | 100–100 mcg |
| Frequency | 7x/wk | 7x/wk |
| Evidence Level | Preclinical | Moderate |
| Indexed Studies | 19+ indexed | 20+ indexed |
| FDA Status | Research Only | Approved |
| Lowest Price | $39.99 / 10mg via Amino Club | $94.97 / 5mg via Bio Longevity Labs |
| Per-mg Cost | $4.00/mg | $18.99/mg |
Mechanism of Action Comparison
How KPV Works
KPV KPV is a tripeptide fragment of alpha-MSH studied for powerfully reducing gut inflammation, investigated as a potential treatment for inflammatory bowel disease and wound healing.
Alpha-MSH fragment that potently suppresses NF-κB inflammatory signaling. Reduces pro-inflammatory cytokines and promotes mucosal healing.
How LL-37 Works
LL-37 LL-37 is the only human antimicrobial cathelicidin peptide studied for directly killing bacteria, viruses, and fungi while also promoting wound healing and immune system activation.
The only human cathelicidin antimicrobial peptide. LL-37 is a 37-amino acid cationic peptide that directly disrupts microbial membranes (bacteria, viruses, fungi) and neutralizes bacterial endotoxins (LPS). Beyond direct antimicrobial action, LL-37 modulates innate immunity by chemoattracting neutrophils, monocytes, and T-cells to infection sites. Promotes wound healing via EGFR-mediated keratinocyte migration and angiogenesis. Demonstrates potent anti-biofilm properties against resistant organisms.
Key Mechanistic Difference
KPV operates as a anti-inflammatory, while LL-37 functions as a antimicrobial peptide — these are fundamentally different pharmacological approaches. LL-37 has a significantly longer half-life (~4 hours) compared to KPV (~30 minutes), which impacts dosing frequency and sustained activity.
Research Evidence
KPV
19 studies- KPV anti-inflammatory effects in murine colitisDalmasso et al. (PLoS One): KPV demonstrates significant anti-inflammatory effects in murine models of inflammatory bowe…Preclinical
- KPV suppresses NF-κB signaling in airway epitheliumStudy shows KPV inhibits p65RelA nuclear import, suppressing NF-κB inflammatory signaling in airway epithelial cells — …Preclinical
- KPV-loaded nanoparticles for oral IBD treatmentHyaluronic acid-functionalized nanoparticle delivery of KPV enhances oral bioavailability and anti-inflammatory efficacy…Preclinical
LL-37
20 studies- LL-37 broad-spectrum antimicrobial and immunomodulatory effectsComprehensive review of LL-37's dual antimicrobial and immunomodulatory functions, including membrane disruption, chemot…Moderate
- LL-37 anti-biofilm activity against resistant pathogensOverhage et al.: LL-37 inhibits biofilm formation by Pseudomonas aeruginosa at sub-MIC concentrations, affecting bacteri…Preclinical
- LL-37 promotes wound healing via EGFR transactivationTokumaru et al.: LL-37 promotes wound re-epithelialization by stimulating keratinocyte migration through EGFR transactiv…Preclinical
Vendor Pricing
· Affiliate links · Prices verified 2026KPV
4 vendorsLL-37
1 vendorAffiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.
Frequently Asked Questions
Can I take KPV and LL-37 together?▼
Yes — KPV and LL-37 are identified as synergistic in interaction databases. They operate through complementary mechanisms and are commonly combined in research protocols.
Which has more research evidence — KPV or LL-37?▼
KPV has 19 indexed studies (highest evidence: Preclinical). LL-37 has 20 indexed studies (highest evidence: Moderate). LL-37 has a more extensive research base.
What is the price difference between KPV and LL-37?▼
At current verified vendor prices, KPV starts at $4.00/mg while LL-37 starts at $18.99/mg. Prices vary by vendor and vial size — see the full vendor comparison below.
Which is better for immune support — KPV or LL-37?▼
Both are researched for immune support. KPV addresses this via gut/injury healing, inflammation reduction. LL-37 approaches it through broad-spectrum antimicrobial, anti-biofilm, wound healing, immune modulation, anti-inflammatory. The optimal choice depends on your specific research protocol and which mechanism aligns with your objectives.
Is KPV or LL-37 FDA-approved?▼
LL-37 has FDA approval (or is derived from an FDA-approved compound). KPV is a research compound without FDA approval for human use. FDA status reflects regulatory evaluation — not necessarily superiority for all research applications.
Related Comparisons
Deep Dive Profiles
Research Use Only — Not Medical Advice
This comparison is provided for educational and research purposes only. It does not constitute medical, prescribing, or treatment advice. Clinical data cited here is sourced from published peer-reviewed trials and FDA labels. Consult a qualified healthcare professional before making any decisions about medications or research compounds. PeptiDex is an informational resource and does not sell pharmaceutical products.